RAD001 and Lenalidomide in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

November 30, 2009

Study Completion Date

November 30, 2009

Conditions
Multiple Myeloma
Interventions
DRUG

RAD001

Dose levels will change: Taken orally either every other day for the first three weeks of each cycle or taken every day for the first three weeks of each cycle.

DRUG

lenalidomide

Dose level will vary: taken orally 30-60 minutes after taking RAD001 every day for the first three weeks of each cycle.

Trial Locations (5)

10021

Memorial Sloan-Kettering Cancer Center, New York

55905

Mayo Clinic, Rochester

02114

Massachusetts General Hospital, Boston

02115

Dana-Farber Cancer Institute, Boston

53226'

Medical College of Wisconsin, Milwaukee

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Dana-Farber Cancer Institute

OTHER

collaborator

Brigham and Women's Hospital

OTHER

collaborator

Mayo Clinic

OTHER

collaborator

Memorial Sloan Kettering Cancer Center

OTHER

collaborator

Medical College of Wisconsin

OTHER

lead

Massachusetts General Hospital

OTHER